Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.
about
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reportsEmerging critical role of molecular testing in diagnostic genitourinary pathologyRegulation of mitochondrial oxidative metabolism by tumor suppressor FLCNFour individually druggable MET hotspots mediate HGF-driven tumor progression.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsA pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.Patient responses to genetic information: studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice.Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinomaMolecular diagnosis and therapy of kidney cancer.Targeted therapies for non-clear renal cell carcinoma.Protein profiling of blood samples from patients with hereditary leiomyomatosis and renal cell cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.Biology of metastatic renal cell carcinoma.Impact of genetics on the diagnosis and treatment of renal cancer.A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.Familial renal cancer: molecular genetics and surgical management.MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer.Trial Watch: Therapeutic vaccines in metastatic renal cell carcinomaIdentifying fragilities in biochemical networks: robust performance analysis of Fas signaling-induced apoptosis.Genetic counseling in renal masses.Kidney cancer: opportunity for disease specific targeted therapy.Biomarkers in clear cell renal cell carcinoma.mTOR pathway in renal cell carcinoma.Immunotherapy for renal cell cancer in the era of targeted therapy.VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinomaTissue biomarkers in renal cell carcinoma: issues and solutionsTargeting the Met signaling pathway in renal cancer.Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells.Aquaporin-1 protein levels elevated in fresh urine of renal cell carcinoma patients: potential use for screening and classification of incidental renal lesions.Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.Rare insights into cancer biology.Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.Cabozantinib as a novel therapy for renal cell carcinoma.
P2860
Q24654382-1C757FD5-4975-4A7B-93BC-0715A47669FDQ27021371-37FEF7C0-B744-4CC4-B175-7DEFFB9D5739Q28506632-2711D893-25D8-4E7A-9D87-A72186CBA8CFQ30581656-98DD15EF-5E83-41CB-858B-9EFC725FF322Q33424270-544E662C-6F29-496E-973C-59BD6A80503EQ33745923-495D3EA5-4DAA-498A-97FE-20A6312E0F1AQ33772820-35D8149C-DEFC-4D66-8281-0F609A75E371Q33780087-514616D0-C66E-4A13-8717-51FDE2BE649DQ33941657-D73026C0-CC94-49A2-9D69-5FD5BE7341F7Q34064359-BEED8956-56BA-4636-ABA0-7940BDF2AEDAQ34065685-7937E348-3545-48B3-9991-681DD0506183Q34412479-DC7F887B-D84A-4697-B8AA-D3EC9C2C6549Q34497888-4CB80C71-7E9C-43B7-AA5E-1012045E4A10Q35167463-BBA6A34F-BE97-4180-AFAC-FEC884E5980FQ35189579-DF9C09B1-E375-4785-91B7-93159309791EQ35194070-161D78C0-8E64-4911-96B7-E75A26E7ECF7Q35567752-270E3095-E45A-4481-9D0F-1DEF12CC44E8Q35687676-F333A55A-C9FC-4DFB-955D-CABA02488379Q35795361-5E3BA755-D03C-47C0-8E77-6B959C3F8BE9Q35799377-0997D57C-D4DA-4CFF-B81E-C9D4F284D5E8Q36856453-81168BB4-01A9-4E34-A01C-099BE5BA19A5Q36969087-05444CD4-C44B-4573-A052-FFE4405E5A13Q36995492-694A111F-B36A-4C06-B97B-526C3E85A72BQ37025951-96B70477-C414-49A4-B772-92D756F778FBQ37086022-9B297775-53F1-4144-BD30-2355A987AFB2Q37183451-98622E36-3708-4324-A623-E164BEB891C7Q37199026-DE6A5DC9-DB25-45B6-AA5F-DBEA0303025FQ37259415-0C0C1983-0973-4A4D-B891-9B5D842F48D0Q37331862-25B094D2-1EBC-4E6F-9414-FE9DEDF105A5Q37575126-50D8A7C7-2BC1-4FB8-B42C-6A3DC491C498Q37720462-57E97FEC-4F9A-49E5-8D51-34B8B7D65D74Q37910970-3E44BCFC-2078-4053-8801-B230986685B7Q38068584-63D71D1C-F32C-42C2-8F2A-0DF20CD0361CQ38071256-0B817E7E-F23C-4169-BFD8-31918FDB5970Q38081379-B16C3459-6750-4B76-9C80-EA644C196724Q38118122-EB2EDB98-D643-4BF4-84AD-06463E48FF34Q38196855-1B782578-F446-4028-AFFB-7BCD8C3B5D57Q38197628-7A86C11F-8242-4FBF-9D34-B820056C21C6Q39236837-C123B81A-4DA0-4670-BAE8-4FD766B00FC5Q39490838-B3B16F4A-A6B8-414A-AE73-7706DB654FDB
P2860
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Identification of the genes fo ...... pecific targeted therapeutics.
@ast
Identification of the genes fo ...... pecific targeted therapeutics.
@en
type
label
Identification of the genes fo ...... pecific targeted therapeutics.
@ast
Identification of the genes fo ...... pecific targeted therapeutics.
@en
prefLabel
Identification of the genes fo ...... pecific targeted therapeutics.
@ast
Identification of the genes fo ...... pecific targeted therapeutics.
@en
P2093
P1476
Identification of the genes fo ...... pecific targeted therapeutics.
@en
P2093
Cathy Vocke
Gladys Glenn
Jorge Toro
Laura S Schmidt
Len Neckers
Lynda Choyke
Maria Merino
Peter A Pinto
Peter Choyke
P304
P356
10.1158/1078-0432.CCR-06-1870
P407
P433
P577
2007-01-01T00:00:00Z